日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial

认知障碍与绝经前和绝经后妇女的化学内分泌治疗与内分泌治疗:RxPONDER随机临床试验的二次分析

Kang, Irene M; Forschmiedt, Jamie K; Loch, Michelle M; Lew, Danika L; Barlow, William E; Gralow, Julie R; Meric-Bernstam, Funda; Albain, Kathy S; Hayes, Daniel F; Lin, Nancy U; Perez, Edith A; Goldstein, Lori J; Rastogi, Priya; Schott, Anne F; Baehner, Rick; Sharma, Priyanka; Tripathy, Debasish; Pusztai, Lajos; Hortobagyi, Gabriel N; Kalinsky, Kevin; Henry, N Lynn

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer

ESR1突变转移性乳腺癌中与依拉司特疗效相关的临床和基因组因素

Lloyd, Maxwell R; Weipert, Caroline M; Ali, Azka; Solomon, Sheila R; Saha, Jayati; Lipsyc-Sharf, Marla D; Hamilton, Erika P; Kalinsky, Kevin; Brufsky, Adam M; Bardia, Aditya; Zhang, Nicole; Wander, Seth A

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

PI3Kα抑制剂和降解剂Inavolisib可利用FGFR2增强PIK3CA突变实体瘤患者和临床前模型的疗效。

Juric Dejan, Song Kyung, Johnson Radia M, Accordino Melissa K, Bedard Philippe L, Cervantes Andrés, Gambardella Valentina, Hamilton Erika, Italiano Antoine, Kalinsky Kevin, Krop Ian E, Oliveira Mafalda, Saura Cristina, Schmid Peter, Turner Nicholas C, Varga Andreea, Gendreau Steven, Hwang Michael S, Kuang Zheng, Lau Jeffrey T, Lin Eva, Pham Trang, Maddalo Danilo, Rees Matthew G, Ronan Melissa M, Roth Jennifer A, Martin Scott, Sodir Nicole M, Sokol Ethan S, Whitfield Zachary J, Wong Alice, Yauch Robert L, Aimi Junko, Cheeti Sravanthi, Fredrickson Jill, Hilz Stephanie, Hafner Marc, Hutchinson Katherine E, Jin Yanling, Peters Ubong, Zingg Daniel, Royer-Joo Stephanie, Shankar Noopur, Schutzman Jennifer L, Jhaveri Komal L, Dey Anwesha

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials

在ER阳性、HER2阴性晚期乳腺癌中,伊姆鲁司群联合阿贝西利与氟维司群联合阿贝西利的疗效比较:三项III期试验的间接治疗比较

Jhaveri, K; Bidard, F C; Kalinsky, K; Neven, P; Rugo, H S; Tolaney, S M; Litchfield, L M; von Laue, C C; Traore, S; Sapunar, F; Li, Y; O'Shaughnessy, J

Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer

谨慎行事,切勿操之过急:为何早期内分泌治疗应等待雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌患者?

Lei, Lan; Bhave, Manali; Kalinsky, Kevin; Gandhi, Shipra

Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2- Metastatic Breast Cancer

HR+/HER2-转移性乳腺癌女性一线治疗及预后模式的社会人口学差异

Vidal, Gregory A; Katz, Julie; Sadetsky, Natalia; Dabrowski, Elizabeth C; Kaufman, Peter A; Verret, Wendy; Stwalley, Brian; Kalinsky, Kevin

Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer

蒽环类药物对基因组高危、淋巴结阴性、HR阳性/HER2阴性乳腺癌的影响

Chen, N; Freeman, J Q; Yarlagadda, S; Atmakuri, A; Kalinsky, K; Pusztai, L; Sparano, J A; Huo, D; Nanda, R; Howard, F M

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01

达托泊单抗德鲁替康对比化疗治疗既往接受过治疗的不可手术/转移性激素受体阳性、人表皮生长因子受体2阴性乳腺癌:TROPION-Breast01研究的主要结果

Bardia, Aditya; Jhaveri, Komal; Im, Seock-Ah; Pernas, Sonia; De Laurentiis, Michelino; Wang, Shusen; Martínez Jañez, Noelia; Borges, Giuliano; Cescon, David W; Hattori, Masaya; Lu, Yen-Shen; Hamilton, Erika; Zhang, Qingyuan; Tsurutani, Junji; Kalinsky, Kevin; Rubini Liedke, Pedro Emanuel; Xu, Lu; Fairhurst, Rick M; Khan, Sabrina; Denduluri, Neelima; Rugo, Hope S; Xu, Binghe; Pistilli, Barbara

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

伊帕他塞替治疗AKT突变肿瘤患者:NCI-MATCH ECOG-ACRIN试验(EAY131)子方案Z1K的结果

McCourt, Carolyn K; Wei, Zihan; Kalinsky, Kevin; Gray, Robert; Wang, Victoria; McShane, Lisa M; Rubinstein, Larry V; Patton, David R; Williams, P Mickey; Hamilton, Stanley R; Force, Jeremy; Pakanati, Anuradha; Tricoli, James V; Conley, Barbara A; Arteaga, Carlos; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study

ASCENT 研究显示,高体重指数与 sacituzumab govitecan 在转移性三阴性乳腺癌患者中的安全性和有效性相关

García-Estévez, L; Bardia, A; Rugo, H S; Carey, L A; Diéras, V C; Loibl, S; Piccart, M; Gianni, L; Kalinsky, K; O'Shaughnessy, J; Hurvitz, S A; Harting, E; Valdez, T; Phan, S; Lai, C; Cortés, J